Drugs / CHM-1101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05627323 | Jun 2023 → Apr 2026 | brain glioblastoma | Chimeric Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHM-1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05627323 ↗ |
| Modality | Cell therapy | “an autologous chlorotoxin-chimeric antigen receptor (CLTX-CAR) cell product” NCT05627323 ↗ |
| Route | Other | “Administered via ICT/ICV dual delivery” NCT05627323 ↗ |